Table 4.
Clinical outcomes and p53 expression by immunohistochemistry for participants on PBTC-041
| Patient ID | Diagnosis | Days of Treatment | Total Courses | Best Response | IHC % p53 |
|---|---|---|---|---|---|
| 1 | CPC | 80 | 2 | PD | 7% |
| 2 | DIPG | 84 | 2 | PD | N.A. |
| 3 | AT/RT | 83 | 2 | PD | 23% |
| 4 | AA | 7 | <1 | PD | 30% |
| 5 | Malignant glioma | 36 | 1 | PD | 8% |
| 6 | GBM | 4 | <1 | PD | >75% |
| 7 | Medulloblastoma | 34 | 1 | PD | 5% |
| 8 | Pineoblastoma | 44 | 1 | PD | 6% |
| 9 | DIPG | 9 | <1 | PD | N.A. |
| 10 | Malignant glioma | 7 | <1 | PD | 5% |
| 11 | Pineoblastoma | 209 | 5 | SD | N.A. |
| 12 | GBM | 14 | <1 | PD | 87% |
| 13 | CPC | 75 | 2 | PD | < 1% |
| 14 | GBM | 303 | 7 | SD | 10% |
| 15 | Medulloblastoma | 37 | 1 | PD | N.A. |
| 16 | GBM | 36 | 1 | PD | 64% |
| 17 | Malignant Glioma | 65 | 2 | SD | N.A. |
Abbreviations: AA, anaplastic astrocytoma; CPC, choroid plexus carcinoma; DIPG, diffuse intrinsic pontine glioma; GBM, glioblastoma; IHC, immunohistochemistry; SD, stable disease; PD, progressive disease.